• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Patterson Companies Inc.

    4/1/25 1:05:28 PM ET
    $PDCO
    Medical Specialities
    Health Care
    Get the next $PDCO alert in real time by email
    8-K
    false 0000891024 0000891024 2025-04-01 2025-04-01

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

    Date of report (Date of earliest event reported)

    April 1, 2025

     

     

    PATTERSON COMPANIES, INC.

    (Exact Name of Registrant as Specified in Its Charter)

     

     

     

    Minnesota   0-20572   41-0886515

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

    1031 Mendota Heights Road

    St. Paul, Minnesota 55120

    (Address of Principal Executive Offices, including Zip Code)

    (651) 686-1600

    (Registrant’s Telephone Number, including Area Code)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered or to be registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Common Stock, par value $.01   PDCO   NASDAQ Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 5.07

    Submission of Matters to a Vote of Security Holders.

    On April 1, 2025, Patterson Companies, Inc. (“Patterson” or the “Company”) held a Special Meeting of Shareholders (the “Special Meeting”) to consider certain proposals related to the Agreement and Plan of Merger (the “Merger Agreement”) dated December 10, 2024 between the Company, Paradigm Parent, LLC, a Delaware limited liability company (“Parent”), and Paradigm Merger Sub, Inc., a Minnesota corporation and a wholly owned subsidiary of Parent (“Merger Sub”). Parent and Merger Sub are indirect subsidiaries of funds managed and advised by Patient Square Capital, a dedicated health care investment firm. The Merger Agreement provides that, among other things, upon the terms and subject to the conditions of the Merger Agreement, at closing (the “Effective Time”), Merger Sub will merge with and into Patterson, with Patterson continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the “Merger”). At the Effective Time, by virtue of the Merger, each share of common stock of the Company issued and outstanding immediately prior to the Effective Time will be converted automatically into the right to receive $31.35 per share in cash. After the Merger, Patterson will cease to be a publicly traded company and will no longer be obligated to file periodic reports with the SEC.

    At the Special Meeting, the Company’s shareholders voted on three proposals as set forth below, each of which was described in detail in the Company’s definitive proxy statement, dated February 27, 2025, and as amended and supplemented on March 24, 2025, as filed with the Securities and Exchange Commission (the “Proxy Statement”). The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each proposal voted upon are set forth below (proposal numbers correspond to the proposal numbers used in the Proxy Statement).

    As of the close of business on February 20, 2025, the record date for the Special Meeting, there were 88,473,849 shares of Patterson common stock par value $0.01 (“Common Stock”) outstanding and entitled to be voted at the Special Meeting. A total of 74,365,208 shares of common stock, representing approximately 84% of the shares of Common Stock outstanding as of the record date for the Special Meeting, were represented in person or by proxy and entitled to vote at the Special Meeting, and constituted a quorum to conduct business at the Special Meeting.

     

      1.

    Proposal 1: The approval of a proposal to adopt and approve the Merger Agreement and the transactions contemplated thereby, including the Merger.

    This proposal was approved as set forth below:

     

    Shares Voted For

     

    Shares Voted Against

     

    Abstentions

    73,918,642   251,952   194,614

     

      2.

    Proposal 2: The approval of a proposal to adjourn the special meeting to a later date or dates if necessary to solicit additional proxies if there are insufficient votes to adopt and approve the Merger Agreement and the transactions contemplated thereby, including the Merger, at the time of the Special Meeting.

    This proposal was approved as set forth below:

     

    Shares Voted For

     

    Shares Voted Against

     

    Abstentions

    68,240,368   5,807,560   317,280

    In light of the approval of Proposal 1, Proposal 2 was rendered moot.

     

      3.

    Proposal 3: The approval, on a non-binding, advisory basis, of certain compensation that will or may become payable to certain named executive officers of the Company in connection with the Merger.


    This proposal was approved as set forth below:

     

    Shares Voted For

     

    Shares Voted Against

     

    Abstentions

    69,422,044   3,842,808   1,100,356

     

    Item 8.01

    Other Events.

    On April 1, 2025, the Company issued a press release announcing the results of the Special Meeting. The press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

     

    Item 9.01

    Financial Statements and Exhibits.

     

    (d)

    Exhibits:

    EXHIBIT INDEX

     

    Exhibit
    No.

      

    Description

    99.1    Press Release of Patterson Companies, Inc., dated April 1, 2025.
    104    Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    PATTERSON COMPANIES, INC.
    By:  

    /s/ Les B. Korsh

        Les B. Korsh
        Chief Legal Officer and Corporate Secretary

    Dated: April 1, 2025

    Get the next $PDCO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PDCO

    DatePrice TargetRatingAnalyst
    12/4/2024$23.00Neutral
    Mizuho
    2/29/2024$34.00 → $28.00Overweight → Neutral
    Piper Sandler
    2/26/2024$36.00Outperform
    Leerink Partners
    5/13/2022$36.00Outperform
    Credit Suisse
    3/3/2022$30.00 → $32.00Equal-Weight
    Morgan Stanley
    1/31/2022$30.00Equal-Weight
    Morgan Stanley
    10/1/2021$38.00Outperform
    Credit Suisse
    More analyst ratings

    $PDCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Tomczik Pamela J returned 7,820 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - PATTERSON COMPANIES, INC. (0000891024) (Issuer)

      4/17/25 2:15:41 PM ET
      $PDCO
      Medical Specialities
      Health Care
    • Director Schrimsher Neil A returned 48,788 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - PATTERSON COMPANIES, INC. (0000891024) (Issuer)

      4/17/25 2:08:45 PM ET
      $PDCO
      Medical Specialities
      Health Care
    • Director Mckoy Philip returned 18,114 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - PATTERSON COMPANIES, INC. (0000891024) (Issuer)

      4/17/25 2:06:32 PM ET
      $PDCO
      Medical Specialities
      Health Care